150281-83-7

Basic information

• Product Name: Pyridine, 2-ethenyl-3-nitro- (9CI)
• Synonyms: Pyridine, 2-ethenyl-3-nitro- (9CI);2-ETHENYL-3-NITRO-PYRIDINE;N-Ethyl-3-cyano-4-Methyl-hydroxy pyridine;3-Nitro-2-vinylpyridine
• CAS NO: 150281-83-7
• Molecular Formula: C₇H₆N₂O₂
• Molecular Weight: 150.13474
• Product Categories: PYRIDINE
• Mol File: 150281-83-7.mol
• Article Data: 11

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Pyridine, 2-ethenyl-3-nitro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2-ethenyl-3-nitro- (9CI)(150281-83-7)
• EPA Substance Registry System: Pyridine, 2-ethenyl-3-nitro- (9CI)(150281-83-7)

Safety Data

• Hazardous Substances Data: 150281-83-7(Hazardous Substances Data)

Upstream product

• 5470-18-8 2-Chloro-3-nitropyridine 
• 75927-49-0 pinacol vinylboronate 
• 7486-35-3 tri-n-butyl(vinyl)tin 
• 20474-38-8 tributyl(vinyl)tin 

Downstream Products

• 1312606-13-5 C₁₅H₁₁FN₂O 
• 1312605-99-4 (2-(2-(methylsulfonyl)phenyl)-1,5-naphthyridin-3-yl)methanol 
• 1312606-04-4 4-Amino-6-((1-(2-(2-(methylsulfonyl)phenyl)-1,5-naphthyridin-3-yl)ethyl)amino)-5-pyrimidinecarbonitrile 
• 1312606-03-3 1-(2-(2-(methylsulfonyl)phenyl)-1,5-naphthyridin-3-yl)ethanamine 
• 1312606-00-0 2-(2-(methylsulfonyl)phenyl)-1,5-naphthyridine-3-carbaldehyde 
• 1312605-59-6 4-amino-6-(((1R)-1-(2-(2-(methylsulfonyl)phenyl)-1,5-naphthyridin-3-yl)ethyl)amino)-5-pyrimidinecarbonitrile 
• 1312605-58-5 4-amino-6-(((1S)-1-(2-(2-(methylsulfonyl)phenyl)-1,5-naphthyridin-3-yl)ethyl)amino)-5-pyrimidinecarbonitrile 
• 1312605-73-4 1-(2-(2-fluorophenyl)-1,5-naphthyridin-3-yl)ethanamine 
• 1312605-72-3 2-(1-(2-(2-fluorophenyl)-1,5-naphthyridin-3-yl)ethyl)-1H-isoindole-1,3 (2H)-dione 
• 1312605-71-2 1-(2-(2-fluorophenyl)-1,5-naphthyridin-3-yl)ethanol 
• 1312605-70-1 2-(2-fluorophenyl)-1,5-naphthyridine-3-carbaldehyde 
• 1312605-68-7 1-(2-(3-fluorophenyl)-1,5-naphthyridin-3-yl)ethanamine 
• 1312605-67-6 2-(1-(2-(3-fluorophenyl)-1,5-naphthyridin-3-yl)ethyl)-1H-isoindole-1,3(2H)-dione 
• 1312605-66-5 1-(2-(3-fluorophenyl)-1,5-naphthyridin-3-yl)ethanol 

Relevant articles and documents

PYRIDAZINONES AND METHODS OF USE THEREOF

Disclosed are therapeutic methods, e.g., of treating kidney diseases, using compounds of Formula (A) in combination with a second therapeutic agent.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.